◎ Sugi Atlas

Atlas / Gene / HTR3B

HTR3B

gene
On this page

Also known as 5-HT3B

Summary

HTR3B (5-hydroxytryptamine receptor 3B, HGNC:5298) is a protein-coding gene on chromosome 11q23.2, encoding 5-hydroxytryptamine receptor 3B (O95264). Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons.

The product of this gene belongs to the ligand-gated ion channel receptor superfamily. This gene encodes subunit B of the type 3 receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor causes fast, depolarizing responses in neurons after activation. It is not functional as a homomeric complex, but a pentaheteromeric complex with subunit A (HTR3A) displays the full functional features of this receptor.

Source: NCBI Gene 9177 — RefSeq curated summary.

At a glance

  • GWAS associations: 5
  • Clinical variants (ClinVar): 84 total
  • Druggable target: yes — 20 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_006028

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:5298
Approved symbolHTR3B
Name5-hydroxytryptamine receptor 3B
Location11q23.2
Locus typegene with protein product
StatusApproved
Aliases5-HT3B
Ensembl geneENSG00000149305
Ensembl biotypeprotein_coding
OMIM604654
Entrez9177

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000260191, ENST00000537778, ENST00000543092

RefSeq mRNA: 2 — MANE Select: NM_006028 NM_001363563, NM_006028

CCDS: CCDS8364, CCDS86249

Canonical transcript exons

ENST00000260191 — 9 exons

ExonStartEnd
ENSE00000747392113932936113933093
ENSE00000747394113932289113932458
ENSE00000795713113942982113943192
ENSE00000930649113931384113931428
ENSE00000930650113931758113931867
ENSE00001106077113909295113909455
ENSE00001106080113944573113944755
ENSE00001130152113945902113949079
ENSE00001130156113904796113904985

Expression profiles

Bgee: expression breadth broad, 59 present calls, max score 72.36.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0277 / max 5.2313, expressed in 19 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
1167640.027719

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
prefrontal cortexUBERON:000045172.36gold quality
tongue squamous epitheliumUBERON:000691970.69gold quality
right frontal lobeUBERON:000281069.06gold quality
diaphragmUBERON:000110367.28gold quality
frontal cortexUBERON:000187066.24gold quality
Brodmann (1909) area 9UBERON:001354066.22gold quality
dorsolateral prefrontal cortexUBERON:000983464.52gold quality
neocortexUBERON:000195064.01gold quality
hair follicleUBERON:000207363.09gold quality
anterior cingulate cortexUBERON:000983561.78gold quality
cingulate cortexUBERON:000302761.77gold quality
olfactory bulbUBERON:000226460.40gold quality
type B pancreatic cellCL:000016960.21gold quality
lower esophagus mucosaUBERON:003583459.44gold quality
cerebral cortexUBERON:000095658.99gold quality
superficial temporal arteryUBERON:000161455.92gold quality
ileal mucosaUBERON:000033155.12silver quality
tibialis anteriorUBERON:000138552.68silver quality
quadriceps femorisUBERON:000137752.50gold quality
telencephalonUBERON:000189352.06gold quality
Brodmann (1909) area 46UBERON:000648351.81gold quality
left ventricle myocardiumUBERON:000656651.81gold quality
vastus lateralisUBERON:000137951.62gold quality
primary visual cortexUBERON:000243651.55gold quality
deltoidUBERON:000147651.29gold quality
superior frontal gyrusUBERON:000266150.89gold quality
epithelial cell of pancreasCL:000008350.29gold quality
dorsal motor nucleus of vagus nerveUBERON:000287050.07gold quality
kidney epitheliumUBERON:000481949.85gold quality
thymusUBERON:000237049.70gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3yes4.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting HTR3B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-7110-3P100.0073.182486
HSA-MIR-6845-3P99.9466.881439
HSA-MIR-552-5P99.9368.561583
HSA-MIR-1343-3P99.8966.781815
HSA-MIR-6783-3P99.8967.922059
HSA-MIR-443799.5265.291266
HSA-MIR-939-3P98.9765.072347
HSA-MIR-445198.8268.171455
HSA-MIR-569198.2367.021335
HSA-MIR-6805-3P98.2367.021334
HSA-MIR-4664-5P98.1765.071020
HSA-MIR-342-5P97.2564.10817

Literature-anchored findings (GeneRIF, showing 40)

  • Cell surface expression of 5-hydroxytryptamine type 3 receptors is controlled by an endoplasmic reticulum retention signal (PMID:12750374)
  • Only 1.3% of antiemetic treatment failure with 5-HT3 receptor antagonists is associated with 5-HT3B receptor gene variant (PMID:12775740)
  • By constructing chimaeric 5-HT3A and 5-HT3B subunits we identified a region (the ‘HA-stretch’) within the large cytoplasmic loop of the receptor that markedly influences channel conductance (PMID:12867984)
  • 5-HT excited human enteric neurons via 5-HT3 receptors, which may comprise both 5-HT3A and 5-HT3B receptor subunits. (PMID:15887114)
  • Six sequence variants found in Gilles de la Tourette syndrome. (PMID:16314763)
  • Different transcriptional regulation of the HTR3B gene by two alternative promoters in the peripheral and the central nervous system leads to expression of transcripts with variations in the 5’ coding sequence. (PMID:17010535)
  • The -100_-102AAG deletion variant of the 5-HT3B receptor gene may affect paroxetine-induced nausea. (PMID:17697394)
  • an HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor (PMID:18184810)
  • the incorporation of the 5-HT3B subunit leads to spontaneous channel opening and altered ligand properties (PMID:18187416)
  • performed electrophoretic mobility shift and luciferase reporter gene assays to elucidate the effect of this -100_-102delAAG deletion polymorphism on the HTR3B promoter activity in PC-12 and HEK293 cells (PMID:18300944)
  • Variants in the HTR3B gene is associated with psychiatric diseases (PMID:18698232)
  • The results suggest that HTR3B is involved in the development of TRS in the Japanese population. (PMID:18807291)
  • 5-HT3B(I143T)-containing 5-HT3AB receptors display significantly reduced cell surface expression and different signalling properties compared with WT 5-HT3AB receptors. (PMID:19008750)
  • 5-HT3R might contribute to the imbalance between excitation and inhibition that characterize the brain of alcoholics (PMID:19185213)
  • Genetic variations in the HTR3A and HTR3B gene seem to be associated with the individual risk of developing postoperative vomiting. (PMID:19713259)
  • an involvement of serotonin receptor type 3B variants in the aetiopathology of eating disorders in humans. (PMID:19741568)
  • Six functional and coding variants of the subunit genes HTR3A, HTR3B as well as the novel HTR3C, HTR3D, and HTR3E subunits in the response to haloperidol or risperidone, were assessed. (PMID:19794330)
  • role of the subunits A and B of the HTR3 receptor using 140 schizophrenia patients taking clozapine for 6 months (PMID:20168265)
  • The HTR3B rs1176744 gain-of-function Ser129 allele predicted alcohol dependence & was more common in men with alcohol and drug dependence. (PMID:20838391)
  • findings indicate that HTR3A and HTR3B polymorphisms may not play a major role in the susceptibility to suicidal behavior in schizophrenia subjects. (PMID:21184810)
  • No associations were found with the 5-HT3B receptor haplotypes and the risk of delayed chemotherapy-induced nausea and vomiting in patients treated with ondansetron and metoclopramide. (PMID:21840870)
  • HTR3A and HTR3B were detected in all investigated brain tissues with the exception of the cerebellum, and large differences in the A:B subunit ratio were observed. (PMID:22832903)
  • Genetic interactions between HTR3B, HTR3A and SLC6A4 play a significant role in nicotine dependence in both European American and African American smokers. (PMID:23290502)
  • Five single nucleotide polymorphisms (SNPs) in HTR3A and HTR3B were found. (PMID:23464988)
  • Data suggest that HTR3A/HTR3B subunits readily form functionally distinct heteromeric receptors; molecular models have been developed regarding affinities of competitive ligands, non-competitive antagonists, and allosteric modulators. [REVIEW] (PMID:23489111)
  • Genetic variability within SLC6A4, HTR3A, and HTR3B contributes to the risk of alcohol dependence and related phenotypes. (PMID:23757001)
  • HTR3B gene variants may contribute to variability in severity of and response to antiemetic therapy for nausea and vomiting of pregnancy. (PMID:23786674)
  • The ability of 5-HT to gate the homomeric or heteromeric receptor appears to rely on the D loop triplet RQY of the complementary face. (PMID:23810831)
  • Polymorphisms in the HTR3B gene are predictors of reduced alcohol drinking in response to ondansetron. (PMID:23897038)
  • the stoichiometry of 5-HT3AB receptors on the plasma membrane (PMID:23972841)
  • This is the first study to show an association between 5-HTR3B and PCS scores, thus suggesting a role of the serotonin pathway in pain catastrophizing. (PMID:24244382)
  • variants in HTR3A, HTR3B, and SLC6A4 interactively contribute to etiology of alcohol, cocaine, and nicotine dependence (PMID:24590108)
  • we found an association of the HTR3B with poor concentration in schizophrenia patients.These results suggest that the HTR3B may be involved in the attention problem of schizophrenia in Korean population. (PMID:24880582)
  • Study demonstrates that the 5-HT3Br1 transcriptional variant of the 5-HT3B subunit can contribute to the functional properties of heteromeric receptors in a similar manner to the originally characterized 5-HT3B subunit (PMID:25951416)
  • The response to ondansetron for PONV was significantly influenced by the -100_-102AAG deletion polymorphisms of the 5-HT3B gene. Thus, the -100_-102AAG deletion variants may be a pharmacogenetic predictor for responsiveness to ondansetron for PONV. (PMID:26256989)
  • the -AAG deletion variant of the 5-HT3B receptor gene may contribute to variability in response to antiemetic therapy for chemotherapy-induced nausea and vomiting (PMID:27488933)
  • A protective haplotype in HTR3B was also associated with OCD (OR = 0.77, CI = 0.63-0.95, permutated P = 0.0179). These results support that common HTR3 variants are involved in OCD and some of its clinical phenotypes (PMID:27616601)
  • Analysis of our small Chinese sample revealed a significant association of HTR3A with bipolar disorder, but yielded no evidence of an association between HTR3B and bipolar disorder. Furthermore, evidence for an association was found for a haplotype of HTR3A. (PMID:27706728)
  • the important role of HTR3B polymorphisms in heroin dependence among the Chinese Han population (PMID:27773795)
  • The HTR3B rs1176744 polymorphisms do not seem to directly influence experimental muscle pain in healthy individuals. However, women reported higher pain intensity and larger pain area than men, which might partly be attributed to genotype. (PMID:28002447)

Cross-species orthologs

3 orthologs

OrganismSymbolGene ID
danio_reriohtr3bENSDARG00000061749
mus_musculusHtr3bENSMUSG00000008590
rattus_norvegicusHtr3bENSRNOG00000006920

Paralogs (45): GABRA3 (ENSG00000011677), GABRA1 (ENSG00000022355), CHRNA3 (ENSG00000080644), GABRP (ENSG00000094755), CHRNA4 (ENSG00000101204), GLRA2 (ENSG00000101958), GABRE (ENSG00000102287), CHRNE (ENSG00000108556), GABRA4 (ENSG00000109158), GLRB (ENSG00000109738), GABRR2 (ENSG00000111886), GABRG2 (ENSG00000113327), CHRNB4 (ENSG00000117971), CHRNA2 (ENSG00000120903), CHRNA10 (ENSG00000129749), CHRND (ENSG00000135902), CHRNA1 (ENSG00000138435), GLRA3 (ENSG00000145451), GABRA6 (ENSG00000145863), GABRB2 (ENSG00000145864), GLRA1 (ENSG00000145888), GABRR1 (ENSG00000146276), CHRNB3 (ENSG00000147432), CHRNA6 (ENSG00000147434), GABRA2 (ENSG00000151834), CHRNB2 (ENSG00000160716), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRB3 (ENSG00000166206), CHRFAM7A (ENSG00000166664), HTR3A (ENSG00000166736), CHRNA5 (ENSG00000169684), CHRNB1 (ENSG00000170175), CHRNA9 (ENSG00000174343), CHRNA7 (ENSG00000175344), HTR3C (ENSG00000178084), GABRG3 (ENSG00000182256), GABRR3 (ENSG00000183185), HTR3E (ENSG00000186038), HTR3D (ENSG00000186090)

Protein

Protein identifiers

5-hydroxytryptamine receptor 3B — O95264 (reviewed: O95264)

Alternative names: Serotonin receptor 3B

All UniProt accessions (2): O95264, H0YFX8

UniProt curated annotations — full annotation on UniProt →

Function. Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons.

Subunit / interactions. Forms homopentameric as well as heteropentameric serotonin-activated cation-selective channel complexes with HTR3A. The homomeric complex is not functional. Heteropentameric complexes display properties which resemble that of neuronal serotonin-activated channels in vivo.

Subcellular location. Postsynaptic cell membrane. Cell membrane.

Tissue specificity. Expressed in the brain cortex, in the caudate nucleus, the hippocampus, the thalamus and the amygdala. Detected in the kidney and testis as well as in monocytes of the spleen, small and large intestine, uterus, prostate, ovary and placenta.

Post-translational modifications. N-glycosylation required for membrane localization.

Domain organisation. The HA-stretch region of HTR3B seems to confer increased conductance to HTR3A/HTR3B heteromers compared to that of HTR3A homomers.

Similarity. Belongs to the ligand-gated ion channel (TC 1.A.9) family. 5-hydroxytryptamine receptor (TC 1.A.9.2) subfamily. HTR3B sub-subfamily.

Isoforms (2)

UniProt IDNamesCanonical?
O95264-11yes
O95264-22

RefSeq proteins (2): NP_001350492, NP_006019* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR006029Neurotrans-gated_channel_TMDomain
IPR006201Neur_channelFamily
IPR006202Neur_chan_lig-bdDomain
IPR0081325HT3_rcptFamily
IPR0081345HT3_rcpt_BFamily
IPR036719Neuro-gated_channel_TM_sfHomologous_superfamily
IPR036734Neur_chan_lig-bd_sfHomologous_superfamily
IPR038050Neuro_actylchol_recHomologous_superfamily
IPR049944LGIC_TM_5-HT3Domain

Pfam: PF02931, PF02932

Catalyzed reactions (Rhea), 3 shown:

  • K(+)(in) = K(+)(out) (RHEA:29463)
  • Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)
  • Na(+)(in) = Na(+)(out) (RHEA:34963)

UniProt features (29 total): glycosylation site 6, topological domain 5, mutagenesis site 5, sequence variant 4, transmembrane region 4, signal peptide 1, chain 1, region of interest 1, disulfide bond 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-O95264-F182.130.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 155–169

Glycosylation sites (6): 52, 96, 138, 168, 203, 287

Mutagenesis-validated functional residues (5):

PositionPhenotype
52reduced molecular weight. very little expression in the cell membrane.
96reduced molecular weight. very little expression in the cell membrane.
138reduced molecular weight. very little expression in the cell membrane.
168reduced molecular weight and cell membrane expression.
203reduced molecular weight. very little expression in the cell membrane.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

IDPathway
R-HSA-112314Neurotransmitter receptors and postsynaptic signal transmission
R-HSA-112315Transmission across Chemical Synapses
R-HSA-112316Neuronal System

MSigDB gene sets: 120 (showing top): CREL_01, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, NKX25_02, GOCC_CELL_SURFACE, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELL_CELL_SIGNALING, EVI1_05, GOBP_REGULATION_OF_POSTSYNAPTIC_MEMBRANE_POTENTIAL, IRF1_Q6, WTGAAAT_UNKNOWN, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_DN, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_SYNAPTIC_SIGNALING, GOCC_NEURON_PROJECTION

GO Biological Process (9): serotonin receptor signaling pathway (GO:0007210), chemical synaptic transmission (GO:0007268), monoatomic ion transmembrane transport (GO:0034220), regulation of membrane potential (GO:0042391), obsolete inorganic cation transmembrane transport (GO:0098662), serotonin-gated cation-selective signaling pathway (GO:0140227), monoatomic ion transport (GO:0006811), regulation of postsynaptic membrane potential (GO:0060078), excitatory postsynaptic potential (GO:0060079)

GO Molecular Function (7): excitatory extracellular ligand-gated monoatomic ion channel activity (GO:0005231), serotonin-gated monoatomic cation channel activity (GO:0022850), transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential (GO:1904315), transmembrane signaling receptor activity (GO:0004888), monoatomic ion channel activity (GO:0005216), extracellular ligand-gated monoatomic ion channel activity (GO:0005230), ligand-gated monoatomic ion channel activity (GO:0015276)

GO Cellular Component (8): plasma membrane (GO:0005886), cell surface (GO:0009986), neuron projection (GO:0043005), synapse (GO:0045202), postsynaptic membrane (GO:0045211), transmembrane transporter complex (GO:1902495), serotonin-activated cation-selective channel complex (GO:1904602), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

CategoryPathways
Transmission across Chemical Synapses1
Neuronal System1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
serotonin receptor activity2
serotonin receptor signaling pathway2
regulation of postsynaptic membrane potential2
transmitter-gated monoatomic ion channel activity2
cellular anatomical structure2
signal transduction1
cellular response to dopamine1
anterograde trans-synaptic signaling1
monoatomic ion transport1
transmembrane transport1
monoatomic ion transmembrane transport1
regulation of biological quality1
serotonin-gated monoatomic cation channel activity1
ligand-gated ion channel signaling pathway1
transport1
regulation of membrane potential1
chemical synaptic transmission, postsynaptic1
extracellular ligand-gated monoatomic ion channel activity1
excitatory postsynaptic potential1
ligand-gated monoatomic cation channel activity1
signaling receptor activity1
monoatomic ion transmembrane transporter activity1
channel activity1
ligand-gated monoatomic ion channel activity1
monoatomic ion channel activity1
ligand-gated channel activity1
membrane1
cell periphery1
plasma membrane bounded cell projection1
cell junction1
synaptic membrane1
postsynapse1
membrane protein complex1
transporter complex1
cation channel complex1
serotonin receptor complex1
neurotransmitter receptor complex1

Protein interactions and networks

STRING

700 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
HTR3BHTR3AP46098978
HTR3BHTR3DQ70Z44874
HTR3BHTR3CQ8WXA8831
HTR3BHTR1EP28566696
HTR3BHTR7P34969690
HTR3BHTR1BP28222676
HTR3BHTR1FP30939666
HTR3BSLC6A4P31645664
HTR3BHTR2AP28223658
HTR3BHTR5AP47898655
HTR3BHTR2BP41595621
HTR3BHTR2CP28335619
HTR3BHTR1AP08908617
HTR3BHTR3EA5X5Y0611
HTR3BHTR1DP28221602

IntAct

4 interactions, top by confidence:

ABTypeScore
HTR3AHTR3Bpsi-mi:“MI:0407”(direct interaction)0.500
HTR3AHTR3Bpsi-mi:“MI:0403”(colocalization)0.500
HTR3BTMEM223psi-mi:“MI:0914”(association)0.350

BioGRID (19): LMF2 (Affinity Capture-MS), SCCPDH (Affinity Capture-MS), CYB5R1 (Affinity Capture-MS), NXPE3 (Affinity Capture-MS), GLRB (Affinity Capture-MS), PXYLP1 (Affinity Capture-MS), LRRC24 (Affinity Capture-MS), SLC9A1 (Affinity Capture-MS), RNASE7 (Affinity Capture-MS), ITPRIP (Affinity Capture-MS), BSCL2 (Affinity Capture-MS), POMT2 (Affinity Capture-MS), C3orf33 (Affinity Capture-MS), ABCB9 (Affinity Capture-MS), SLC15A4 (Affinity Capture-MS)

ESM2 similar proteins: A2A259, A5X5Y0, H2Q5A1, O46547, O70212, O95264, O97741, P01906, P01909, P02713, P02715, P02716, P04758, P04759, P04760, P07510, P09660, P09690, P11230, P13536, P18916, P20782, P23979, P25109, P25110, P35563, P37088, P37089, P46098, P55270, P78334, Q04844, Q07001, Q14246, Q5Y4N8, Q60HE8, Q61180, Q61549, Q70Z44, Q7Z418

Diamond homologs: A5X5Y0, O70212, O95264, P04757, P05376, P18845, P19370, P22770, P23979, P26153, P32297, P35563, P36544, P43143, P43679, P46098, P48182, P49581, P49582, P54131, Q05941, Q07263, Q15825, Q494W8, Q5IS76, Q68RJ7, Q70Z44, Q866A2, Q8R4G9, Q8WXA8, Q9I8C7, Q9JHJ5, Q9JJ16, A8WQK3, A8XNX8, O16926, O70174, O76554, P02716, P02717

SIGNOR signaling

2 interactions.

AEffectBMechanism
serotonin“up-regulates activity”HTR3B“chemical activation”
HTR3Bup-regulatesExcitatory_synaptic_transmission

Disease & clinical

Clinical variants and AI predictions

ClinVar

84 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance74
Likely benign5
Benign2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1711 predictions. Top by Δscore:

VariantEffectΔscore
11:113909453:GTG:Gdonor_gain1.0000
11:113931863:GAGTT:Gdonor_gain1.0000
11:113931865:GTT:Gdonor_gain1.0000
11:113931866:TT:Tdonor_gain1.0000
11:113931868:G:GGdonor_gain1.0000
11:113932284:T:Gacceptor_gain1.0000
11:113932287:A:AGacceptor_gain1.0000
11:113932287:AGTGT:Aacceptor_gain1.0000
11:113932288:G:GGacceptor_gain1.0000
11:113932288:GT:Gacceptor_gain1.0000
11:113932288:GTGTG:Gacceptor_gain1.0000
11:113932934:A:AGacceptor_gain1.0000
11:113932935:G:GAacceptor_gain1.0000
11:113933007:GACA:Gdonor_gain1.0000
11:113933011:G:GGdonor_gain1.0000
11:113943049:T:Aacceptor_gain1.0000
11:113944570:CAG:Cacceptor_loss1.0000
11:113944572:G:GAacceptor_loss1.0000
11:113945901:GA:Gacceptor_gain1.0000
11:113909452:TGTGG:Tdonor_loss0.9900
11:113909454:TGGTA:Tdonor_loss0.9900
11:113909456:G:Cdonor_loss0.9900
11:113909456:G:GGdonor_gain0.9900
11:113909457:T:Gdonor_loss0.9900
11:113909458:A:Cdonor_loss0.9900
11:113931752:TAACA:Tacceptor_loss0.9900
11:113931754:ACAG:Aacceptor_loss0.9900
11:113931755:CAGGT:Cacceptor_loss0.9900
11:113931756:A:Tacceptor_loss0.9900
11:113931866:TTG:Tdonor_loss0.9900

AlphaMissense

2903 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
11:113943063:A:CS260R0.980
11:113943065:C:AS260R0.980
11:113943065:C:GS260R0.980
11:113943033:A:CS250R0.974
11:113943035:C:AS250R0.974
11:113943035:C:GS250R0.974
11:113932404:T:CF162L0.971
11:113932406:T:AF162L0.971
11:113932406:T:GF162L0.971
11:113944611:A:CS316R0.964
11:113944613:C:AS316R0.964
11:113944613:C:GS316R0.964
11:113931841:G:CW114C0.955
11:113931841:G:TW114C0.955
11:113932443:A:CS175R0.955
11:113932445:C:AS175R0.955
11:113932445:C:GS175R0.955
11:113943107:G:CK274N0.953
11:113943107:G:TK274N0.953
11:113931761:T:AW88R0.946
11:113931761:T:CW88R0.946
11:113932410:T:CF164L0.945
11:113932412:T:AF164L0.945
11:113932412:T:GF164L0.945
11:113931839:T:AW114R0.943
11:113931839:T:CW114R0.943
11:113933018:G:CW207C0.943
11:113933018:G:TW207C0.943
11:113931763:G:CW88C0.941
11:113931763:G:TW88C0.941

dbSNP variants (sampled 300 via entrez): RS1000086244 (11:113947345 G>A), RS1000149846 (11:113912624 T>G), RS1000188228 (11:113918412 C>T), RS1000272816 (11:113947479 C>T), RS1000292402 (11:113915675 T>C), RS1000351406 (11:113900554 C>T), RS1000358870 (11:113899509 A>T), RS1000414678 (11:113925056 G>A), RS1000427565 (11:113943373 A>G,T), RS1000471718 (11:113899122 G>A), RS1000554874 (11:113905805 A>G), RS1000589849 (11:113931076 A>AT), RS1000676391 (11:113942800 AT>A,ATT), RS1000708426 (11:113942433 T>C), RS1000767681 (11:113938059 C>A,G)

Disease associations

OMIM: gene MIM:604654 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

StudyTraitp-value
GCST002606_17Prostate cancer3.000000e-08
GCST002606_36Prostate cancer5.000000e-08
GCST003140_1Chronic kidney disease5.000000e-06
GCST010397_46Gut microbiota (bacterial taxa, rank normal transformation method)2.000000e-06
GCST010397_55Gut microbiota (bacterial taxa, rank normal transformation method)3.000000e-06

EFO canonical traits (1, from GWAS)

EFO IDTrait name
EFO:0007874gut microbiome measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2094132 (PROTEIN COMPLEX GROUP), CHEMBL2096904 (PROTEIN FAMILY), CHEMBL2111332 (PROTEIN COMPLEX), CHEMBL3895 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

20 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 689,583 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL1112ARIPIPRAZOLE424,205
CHEMBL1729CISAPRIDE414,365
CHEMBL289469GRANISETRON4431
CHEMBL3NICOTINE4184,969
CHEMBL42CLOZAPINE437,581
CHEMBL46ONDANSETRON441,386
CHEMBL56564TROPISETRON419,312
CHEMBL6437MIANSERIN414,778
CHEMBL708ZIPRASIDONE421,536
CHEMBL715OLANZAPINE440,057
CHEMBL86METOCLOPRAMIDE437,825
CHEMBL11IMIPRAMINE448,893
CHEMBL1189679PALONOSETRON49,399
CHEMBL39SEROTONIN3186,160
CHEMBL18041ZACOPRIDE21,760
CHEMBL18772QUIPAZINE21,108
CHEMBL2107804BEMESETRON21,019
CHEMBL478CHLOROPHENYLPIPERAZINE23,138
CHEMBL7257MEBUFOTENIN21,595
CHEMBL214268PHA-543613166

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

5 annotations.

VariantTypeLevelDrugsPhenotypes
rs11606194Toxicity3nicotineTobacco Use Disorder
rs1176744Toxicity4paroxetineMental Disorders
rs2276307Toxicity3atorvastatin;pravastatin;simvastatinMyalgia
rs3758987Toxicity3heroinHeroin Dependence
rs3758987Toxicity3nicotineTobacco Use Disorder

PharmGKB variants

13 variants.

VariantGenesLevelScore#Clin annotsDrugs
rs1176744HTR3B4-0.251paroxetine
rs1176746HTR3B0.000
rs2276305HTR3B0.000
rs2276307HTR3B32.501atorvastatin;pravastatin;simvastatin
rs3758987HTR3B33.002heroin;nicotine
rs10789970HTR3B0.000
rs11214763HTR3B0.000
rs45460698HTR3B0.000
rs7943062HTR3B0.000
rs11606194HTR3B33.001nicotine
rs7103572HTR3B0.000
rs3782025HTR3B0.000
rs1672717HTR3B0.000

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: lgic — 5-HT3 receptors

Binding affinities (BindingDB)

4 measured of 4 human assays (4 total across all organisms); most potent 4 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValue
5’-phenyl-(2’R)-spiro[4-azabicyclo[2.2.2]octane-2,2’-furo[2,3-b]pyridine]KI73 nM
[2,2’]Bithiophenyl-5-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amideKI1040 nM
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-phenylthiophene-2-carboxamideKI2020 nM
5-Phenyl-thiophene-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amideKI2020 nM

ChEMBL bioactivities

334 potent at pChembl≥5 of 340 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
11.00Kd0.01nMCHEMBL143197
10.70Kd0.01995nMGRANISETRON
10.60Kd0.02512nMTROPISETRON
10.60Kd0.02512nMCHEMBL143197
10.20Kd0.0631nMTROPISETRON
10.15Ki0.071nMCHEMBL325422
10.10Kd0.07943nMONDANSETRON
10.10Kd0.07943nMGRANISETRON
10.10Kd0.07943nMZACOPRIDE
10.09IC500.08128nMCHEMBL416662
9.90Kd0.1259nMGRANISETRON
9.85Kd0.14nMPALONOSETRON
9.80Kd0.16nMGRANISETRON
9.80Kd0.1585nMCHEMBL323208
9.80Kd0.1585nMCHEMBL40935
9.74Kd0.18nMPALONOSETRON
9.70Kd0.2nMGRANISETRON
9.66Kd0.22nMGRANISETRON
9.64Ki0.23nMCHEMBL43355
9.64Ki0.23nMCHEMBL327197
9.64Kd0.23nMPALONOSETRON
9.60Kd0.25nMGRANISETRON
9.54IC500.2884nMCHEMBL299634
9.49Ki0.32nMCHEMBL111448
9.47Kd0.34nMPALONOSETRON
9.45IC500.3548nMCHEMBL53416
9.41Ki0.39nMCHEMBL111059
9.40Kd0.3981nMONDANSETRON
9.36Ki0.44nMCHEMBL113742
9.35IC500.4467nMQUIPAZINE
9.35Ki0.45nMCHEMBL325349
9.33Ki0.47nMCHEMBL113519
9.32Kd0.48nMPALONOSETRON
9.32Ki0.48nMCHEMBL320480
9.30Kd0.5012nMBEMESETRON
9.29Ki0.51nMCHEMBL315861
9.29Ki0.51nMCHEMBL333371
9.24Ki0.58nMCHEMBL112941
9.20Kd0.631nMCHEMBL40324
9.20Kd0.631nMONDANSETRON
9.17Ki0.68nMCHEMBL112237
9.16Ki0.69nMCHEMBL109322
9.15Ki0.7nMCHEMBL13535
9.11Kd0.78nMGRANISETRON
9.10IC500.7943nMCHEMBL49932
9.10IC500.7943nMCHEMBL334923
9.08Ki0.83nMCHEMBL287987
9.07Ki0.86nMCHEMBL321477
9.06IC500.88nMPALONOSETRON
9.06Ki0.88nMCHEMBL325235

PubChem BioAssay actives

297 with measured affinity, of 628 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
7-(4-prop-2-enylpiperazin-1-yl)-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic50<0.0001uM
1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide6027: Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heartkd<0.0001uM
7-(4-benzylpiperazin-1-yl)-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic50<0.0001uM
4-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-7-chloropyrrolo[1,2-a]quinoxaline6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0001uM
(1-methylindol-3-yl)-(4,5,6,7-tetrahydro-3H-benzimidazol-5-yl)methanone5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0001uM
Ondansetron6027: Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heartkd0.0001uM
Palonosetron1056977: Binding affinity to human 5-HT3B receptor H73A mutant after 24 hrs by liquid scintillation counting analysiskd0.0001uM
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate6026: Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vaguskd0.0001uM
4-(4-methylpiperazin-1-yl)pyrrolo[1,2-a]quinoxaline6335: Binding affinity towards 5-hydroxytryptamine 3 receptorki0.0002uM
6-(4-methylpiperazin-1-yl)-7,8,9,10-tetrahydrophenanthridine6335: Binding affinity towards 5-hydroxytryptamine 3 receptorki0.0002uM
(2-methyl-4-oxo-2-azabicyclo[3.3.1]nonan-8-yl) 1H-indole-3-carboxylate6028: Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heartkd0.0002uM
(4-oxo-2-azatricyclo[3.3.1.02,7]nonan-8-yl) 1H-indole-3-carboxylate200911: Potency was evaluated on rabbit heart serotonergic receptorskd0.0002uM
4-(4-benzylpiperazin-1-yl)-7-chloropyrrolo[1,2-a]quinoxaline6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0003uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-oxo-1-propan-2-ylquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0003uM
4-(4-benzylpiperazin-1-yl)pyrrolo[1,2-a]quinoxaline6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0004uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-butoxyquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0004uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(2-methylpropoxy)quinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0004uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-oxo-1-propylquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0004uM
2-piperazin-1-ylquinoline6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0004uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-(2-methylpropyl)-2-oxoquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0005uM
7-fluoro-4-(4-methylpiperazin-1-yl)pyrrolo[1,2-a]quinoline6335: Binding affinity towards 5-hydroxytryptamine 3 receptorki0.0005uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-oxo-1-phenylquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0005uM
1-butyl-4-hydroxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-oxoquinoline-3-carboxamide5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0005uM
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3,5-dichlorobenzoate6027: Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heartkd0.0005uM
(1,1-dimethylpiperidin-1-ium-4-yl)-(1H-indol-3-yl)methanone iodide6028: Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heartkd0.0006uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-methoxyquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0006uM
2-(3,4,5-trichlorophenyl)guanidine6339: Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.ki0.0007uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-butyl-2-oxoquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0007uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(2-methylpropyl)quinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0007uM
10-(4-methylpiperazin-1-yl)-9-azatetracyclo[11.2.1.02,11.03,8]hexadeca-2(11),3,5,7,9-pentaene6335: Binding affinity towards 5-hydroxytryptamine 3 receptorki0.0008uM
7-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0008uM
N,N-dimethyl-2-[(Z)-(3-methylthieno[2,3-b]pyrrolizin-8-ylidene)amino]oxyethanamine6316: Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptoric500.0008uM
8-(4-prop-2-enylpiperazin-1-yl)-5-thia-1,7-diazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0009uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-pentoxyquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0009uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-ethoxyquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0009uM
7-(4-methylpiperazin-1-yl)-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0010uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dimethylbenzoate6027: Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heartkd0.0010uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-oxo-1-pentylquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0010uM
8-(4-benzylpiperazin-1-yl)-3-thia-1,7-diazatricyclo[7.3.0.02,6]dodeca-2(6),4,7,9,11-pentaene1855131: Binding affinity to 5-HT3 receptor (unknown origin) assessed as inhibition constantki0.0010uM
1-azabicyclo[2.2.2]octan-3-yl 1H-indole-3-carboxylate6344: In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determinedki0.0011uM
Imipramine2198785: Inhibition of 5HT receptor (unknown origin)ic500.0011uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-ethyl-2-oxoquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0011uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-hexyl-2-oxoquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0011uM
8-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]-5-thia-1,7-diazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0012uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-benzyl-2-oxoquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0013uM
4-amino-N-[(4S,5R)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide6028: Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heartkd0.0013uM
4-hydroxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-oxo-1-phenylquinoline-3-carboxamide5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0014uM
7-piperazin-1-yl-2,8,13-triazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene6355: Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligandic500.0015uM
N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-4-oxo-1H-quinoline-3-carboxamide5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0015uM
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-(3-methylbutyl)-2-oxoquinoline-4-carboxylate5980: Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15ki0.0015uM

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

ChemicalActions (top 5)PubMed papers
bisphenol Aaffects cotreatment, increases methylation, increases expression2
CGP 52608affects binding, increases reaction1
Resveratrolaffects cotreatment, decreases expression1
Fulvestrantaffects cotreatment, increases methylation1
Ethanolaffects binding, increases activity, increases reaction1
1-Propanolaffects binding, increases activity, increases reaction1
Pentanolsaffects binding, increases activity, increases reaction1
Hexanolsaffects binding, decreases reaction, increases activity1
Octanolsincreases activity, affects binding, decreases reaction1
Arsenicaffects methylation1
Benzo(a)pyreneaffects methylation1
Copperaffects cotreatment, decreases expression1
Dopamineaffects binding, increases activity1
Serotoninaffects binding, increases activity, increases reaction, decreases reaction1
Aflatoxin B1increases methylation1
Hydroxymethylglutaryl-CoA Reductase Inhibitorsincreases response to substance1
Okadaic Aciddecreases expression1
1-Butanolaffects binding, increases activity, increases reaction1

ChEMBL screening assays

194 unique, capped per target: 129 binding, 64 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4368604BindingDisplacement of [3H]BRL 43694 from recombinant human 5-HT3 receptor at 10 uM after 120 mins by radiometric scintillation analysis relative to controlDesign, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system. — Bioorg Med Chem Lett
CHEMBL615717FunctionalCompound was tested for agonistic activity against 5-HT uptakeFirst tricyclic oximino derivatives as 5-HT3 ligands. — Bioorg Med Chem Lett
CHEMBL4413391ADMETAntagonist activity at serotonin receptor in human PBMC assessed as inhibition of PMA-stimulated superoxide anion generation at 10 uM preincubated for 1 hr followed by PMA-stimulation and measured after 30 mins by spectrophotometric methodIdentification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening. — Eur J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 80

This page pulls from 80 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot